Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Eli Lilly Invests $3B to Expand Wisconsin Factory to Help Meet Demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments
Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.
Eli Lilly announces $3 billion expansion of Wisconsin facility to meet growing demand for GLP-1 drugs
CNBC's Angelica Peebles joins 'Closing Bell' to report on Eli Lilly announcing a $3 billion expansion of its Wisconsin facility to meet growing demand for GLP-1 drugs.
Lilly planning $3B expansion of Wisconsin plant to boost production
Eli Lilly (NYSE:LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its recently acquired manufacturing facility in Kenosha County, Wisconsin. Lilly expects to start construction on the expansion in 2025,
1d
on MSN
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
STAT
13h
Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
FiercePharma
1d
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
BioPharma Dive
1d
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
9d
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
STAT
1d
‘Leptin’s last chance’: Mouse study says infamous weight loss drug failure could boost GLP-1s
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
BioPharma Dive
9d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
13h
Healthy Returns: Wall Street mulls over Amgen's weight loss drug data
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
8h
on MSN
FDA chief defends work on obesity, food to US Senate as agency awaits fierce critic RFK Jr
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
9h
The answer to the obesity crisis is staring Keir in the face – so why is he refusing to act?
Oh dear, Keir. In late October, I issued a 100-day appeal for the gloomsters and doomsters to pipe down and just let the new ...
McKnight's Long-Term Care News
8d
CMS’ obesity drug coverage implications for nursing home patients
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...
2d
on MSN
Altimmune CEO on what’s next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback